Connect with us
DAPA Banner

Business

Cornwall wins government backing for independent devolution as Devon merger ruled out

Published

on

Business Live

It means the Duchy will remain separate from Devon in its devolution journey

Sunshine at Newquay harbour

Sunshine at Newquay harbour(Image: Western Morning News)

Cornwall has taken another significant stride in its devolution ambitions with a decision that “firms up” the county’s position against merging with Devon as a cross-border local authority. Cornwall Council’s Liberal Democrat/Independent cabinet today (Wednesday, March 18) voted to accept, in principle, the Secretary of State for Housing, Communities and Local Government’s proposal to explore designating the authority as a Single Foundation Strategic Authority.

Advertisement

In what represents a prime example of local government terminology, cabinet members backed the initiative which would be “consistent with the request for a Cornwall-only Spatial Development Strategy footprint to ensure coterminosity between the two”.

Put simply, subject to satisfaction with the broader details, Cornwall Council will avoid amalgamation with any other South West authority and will persist in pursuing greater devolution from Westminster, with a long-term goal of administering its own affairs akin to fellow Celtic nations, Wales and Scotland.

Today’s decision follows correspondence last November from the Secretary of State for Housing, Communities and Local Government, Steve Reed, which set out his proposals regarding enhanced devolution to Cornwall.

He said: “We also recognise the strong enthusiasm in Cornwall for devolution and the benefits it provides. In recognition of Cornwall’s distinct local identity and history of programme delivery across the Cornwall footprint, the Government is minded, on an exceptional basis, to work with you to explore designating the council as a Single Foundation Strategic Authority.”

Advertisement

Cornwall Council leader Cllr Leigh Frost said: “I don’t want anyone to think ‘oh devolution, it’s the end of the journey now’. This is absolutely the start for us to really take that fight to the next level, but we have to operate within the frameworks that the Government says we have to operate in.

Cllr Leigh Frost pictured in the chamber after being elected as the new leader of Cornwall Council  (Pic: Lee Trewhela / LDRS)

Cllr Leigh Frost pictured in the chamber(Image: Local Democracy Reporting Service)

“The long-term aim is a devolution arrangement that sits similarly to Wales and Scotland, but we aren’t going to get there tomorrow and we have to use the opportunities that we’ve got in front of us now to get there.

“The key thing is to protect the Cornwall footprint, make sure we get extended powers for Cornwall and then we can make a stronger case as we go forward to continue making those arguments of why we should be a distinct and separate nation in the United Kingdom.”

Cllr Tim Dwelly, cabinet member for economic regeneration and investment, added: “It’s really quite an amazing result for us; for those of us who were opposed to a Mayor of Cornwall being imposed against the will of the people and for the idea of combining with Devon.

Advertisement

“For anyone who is aware of the change of political control of this authority, this is probably one of the biggest changes that we have absolutely firmed up – the idea that Cornwall is not going to combine with Devon and Government has recognised that.

“I don’t think it’s a small thing. I think it took a lot of tough politics.”

Cllr Dick Cole, leader of Mebyon Kernow, acknowledged there remained considerable ground to cover before realising his aspiration of comprehensive and substantive devolution as an independent Cornish nation.

“This is just a stepping stone. From my perspective, we’re still so far back from where we should be, it’s off the scale. If we were talking about which step we were on, I’d say we’re still only two steps up Bedruthan Steps.

Advertisement

“We’re talking about greater recognition for the Cornish nation but we’re doing it in a local government context. We’ve made progress but we have to up the ante even further.”

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Form 13G Zeta Network Group For: 18 March

Published

on


Form 13G Zeta Network Group For: 18 March

Continue Reading

Business

Selling Sheffield Wednesday

Published

on

Selling Sheffield Wednesday

BBC Sport looks at one of England’s most famous football clubs’ fight for survival.

Continue Reading

Business

Bentley workers 'shocked and angry' at job cuts

Published

on

Bentley workers 'shocked and angry' at job cuts

A union says the announcement came as a blow to employees with up to 275 positions at risk.

Continue Reading

Business

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Published

on

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025.

Kyle Grillot | Bloomberg | Getty Images

Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Advertisement

The FDA approved the pill, Icotyde, to treat moderate to severe plaque psoriasis, an autoimmune condition that causes rough patches of skin. Patients typically start treatment with topical medications.

If those don’t work, they advance to pills or shots. J&J sees Icotyde becoming the first-line systematic treatment for psoriasis, in between topicals and shots.

Drugmakers have been developing more advanced medicines than standard topicals, turning psoriasis into a highly competitive space. Icotyde targets the same IL-23 receptor as best-selling shots like J&J’s Tremfya and AbbVie‘s Skyrizi, giving patients an oral alternative to some of the most advanced — and most expensive — drugs on the market.

“To be able to to be able to have something that is relatively simple, that offers that level of clearance, trusted safety profile, and in a simple pill, we think is going to be revolutionary,” said Jennifer Taubert, chairman of J&J Innovative Medicine.

Advertisement

J&J estimates about 8 million people in the U.S. have plaque psoriasis, and that 75% of people don’t advance from topicals to shots because of reasons like fearing needles. Taubert sees Icotyde appealing to those patients.

“We believe having the type of profile that Icotyde has in a simple, once-daily oral pill, we think it’s going to be an absolute game changer for patients,” Taubert said.

J&J hasn’t announced how much Icotyde will cost beyond saying the company will help people pay for the medicine. Rival shots Tremfya and Skyrizi cost around $100,000 a year.

J&J sees peak annual sales of Icotyde exceeding $5 billion once it’s approved for other autoimmune conditions. It’s testing the drug for psoriatic arthritis, ulcerative colitis and Crohn’s disease.

Advertisement

Shares of J&J slid one-quarter of a percent Wednesday while shares of Skyrizi-maker AbbVie fell more than 4%. Protagonist Therapeutics, a biotech company that developed Icotyde with J&J, was trading about flat.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Brightstar Lottery stock hits 52-week low at 12.6 USD

Published

on


Brightstar Lottery stock hits 52-week low at 12.6 USD

Continue Reading

Business

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Published

on

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Continue Reading

Business

US holds interest rates as Iran war triggers oil shock

Published

on

US holds interest rates as Iran war triggers oil shock

The US central bank is moving cautiously, despite pressure from the president to cut interest rates.

Continue Reading

Business

Big Tech’s Huge Conglomerate Premium

Published

on

Big Tech’s Huge Conglomerate Premium

Big Tech’s Huge Conglomerate Premium

Continue Reading

Business

Datassential reveals top emerging foodservice chains

Published

on

Datassential reveals top emerging foodservice chains

Top chains specialized in focused concepts and tapped into trending flavors.

Continue Reading

Business

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Published

on

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Continue Reading

Trending

Copyright © 2025